Back to Browse Journals » Open Access Journal of Clinical Trials » Volume 3

The future of the pharmaceutical, biological and medical device industry

Authors Burgess LJ, Terblanche M

Published 7 September 2011 Volume 2011:3 Pages 45—50


Review by Single-blind

Peer reviewer comments 4

Lesley J Burgess, Marli Terblanche
TREAD Research/Cardiology Unit, Department of Internal Medicine, Tygerberg Hospital and University of Stellenbosch, Parow, South Africa

Abstract: Numerous factors contribute to the declining pharmaceutical industry on the one hand and the rapidly growing generic industry together with the growing importance of medical devices and biologicals on the other. It is clear that the pharmaceutical industry is going to undergo a change in the next decade in order to meet the current challenges facing it and ultimately sustain its profitability and growth. This paper aims to identify a number of fairly obvious trends that are likely to have a significant impact on the product development pipeline in the next decade. It is more than clear that the current production pipeline for pharmaceutical, biotechnology and medical device industries is no longer sustainable and that urgent interventions are required in order to maintain its current level of profitability.

Keywords: pharmaceutical industry, personalized medicine, trends, generics, biotechnology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Examining the readability of patient-informed consent forms

Marli Terblanche, Lesley Burgess

Open Access Journal of Clinical Trials 2010, 2:157-162

Published Date: 19 October 2010

Readers of this article also read:

A new recombinant factor VIII: from genetics to clinical use

Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H

Drug Design, Development and Therapy 2015, 9:3817-3819

Published Date: 23 July 2015

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics

Farrugia A, Noone D, Schlenkrich U, Schlenkrich S, O’Mahony B, Cassar J

Journal of Blood Medicine 2015, 6:185-195

Published Date: 15 June 2015

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A

George LA, Camire RM

Journal of Blood Medicine 2015, 6:131-141

Published Date: 24 April 2015

Romiplostim as a treatment for immune thrombocytopenia: a review

Chalmers S, Tarantino MD

Journal of Blood Medicine 2015, 6:37-44

Published Date: 19 January 2015

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation

Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K

Journal of Blood Medicine 2012, 3:157-161

Published Date: 5 December 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Induced pluripotent stem cells: advances to applications

Timothy J Nelson, Almudena Martinez-Fernandez, Satsuki Yamada, et al

Stem Cells and Cloning: Advances and Applications 2010, 3:29-37

Published Date: 22 December 2009